GlycoMimetics reports Q4 EPS (19c), consensus (17c)

As of December 31, 2022, GlycoMimetics had cash and cash equivalents of $47.9M as compared to $90.3M as of December 31, 2021. In the first quarter, GlycoMimetics raised a total of $28.7M from sales of shares of common stock under its existing ATM facility. "In 2022, we made great strides in our continued organizational evolution, strengthening our leadership team and financial position as we aspire to become a commercial-stage company capable of delivering uproleselan to R/R AML patients in need of innovative new treatment options," said Harout Semerjian, CEO of GlycoMimetics. "Patients continue to live longer in our pivotal Phase 3 study of uproleselan, with duration of median follow-up for the blinded, pooled patient population now at a remarkable 25 months. Our Phase 3 AML trial projects to have the longest duration of median follow-up at time of primary analysis of any study, to our knowledge, previously conducted in this disease area. We remain optimistic and excited about the potential of uproleselan to improve overall survival in R/R AML."